Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0013 • ACR Convergence 2025
Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases
Xiaofeng Zhao¹, Xiaoqing Liu¹, Yuxi Yan², Tiezheng Liu³, Yong Fu³, Yulan Hu², Kangmin Zhou², Minyun Zhou⁴, Yingying Hu² and Shunwei Zhu², ¹State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ²State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), ³State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ⁴State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing
Background/Purpose: B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that contributes to the regulation of T cell, B cell and dendritic cell…
Abstract Number: 2694 • ACR Convergence 2025
Effect of Deucravacitinib Treatment on Renal Dysfunction–Associated Plasma Biomarkers From a Phase 2 Study in Patients With Systemic Lupus Erythematosus
Amit Saxena¹, Chun Wu², Brad Rovin³, Zahi Touma⁴, Xueer Chen⁵, Ilias Kouris⁶ and Jinqi Liu⁵, ¹Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ²Bristol Myers Squibb, Princeton, ³The Ohio State University, Columbus, OH, ⁴University of Toronto, Toronto, ON, Canada, ⁵Bristol Myers Squibb, Princeton, NJ, ⁶Bristol Myers Squibb, Boudry, Switzerland
Background/Purpose: Plasma biomarkers may play a role in understanding kidney health in patients with lupus, particularly in terms of early detection of lupus nephritis (LN),…
Abstract Number: 2601 • ACR Convergence 2025
Characterisation of immunometabolic reprogramming at the single cell level in patients with systemic lupus erythematosus and preclinical autoimmunity
Antonios Psarras¹, Sinibaldo Arocha², Liezel Tamon², David Ahern², Md Yuzaiful Md Yusof³, Ed Vital⁴ and Alexander Clarke⁵, ¹University of Oxford, Oxford, England, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³University of Leeds, Leeds, United Kingdom, ⁴University of Leeds, Leeds, England, United Kingdom, ⁵Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is characterised by innate immune activation and autoantibodies against nucleic self-antigens. The metabolic state of immune cells is emerging as…
Abstract Number: 2467 • ACR Convergence 2025
Complete Renal Responses and Safety for Belimumab Versus Placebo in a Post Hoc Mycophenolate Mofetil Subgroup with Active Proliferative Lupus Nephritis
Richard Furie¹, Hans-Joachim Anders², George Bertsias³, Ana Delgado⁴, Roger A. Levy⁵, Paula Curtis⁶, Ciara O'Shea⁷, Ryan Tomlinson⁸ and Brad Rovin⁹, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Hospital of LMU Munich, Department of Medicine IV, Munich, Germany, ³Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece, ⁴GSK, Immunology Medical Affairs, London, United Kingdom, ⁵GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁶GSK, Biostatistics, London, United Kingdom, ⁷Global Medical Affairs, GSK, Dublin, Ireland, ⁸GSK, Development – R&D, Collegeville, PA, ⁹The Ohio State University, Columbus, OH
Background/Purpose: Belimumab, a human IgG1λ monoclonal antibody that selectively binds B-lymphocyte stimulator, was first approved in 2011. It is the only biologic approved for LN…
Abstract Number: 2449 • ACR Convergence 2025
Patient Characteristics, Treatment and Prognosis in Patients with Neuromyelitis OpticaSpectrum Disorder Coexisting with Systemic Lupus Erythematosus or Sjögren’s Syndrome: An Analysis Using Japanese Inpatient Database
Hiroshi Shiba¹, Mikio Nakajima², Kaito Nakamura³, Yusuke Sasabuchi⁴, Hiroyuki Ohbe⁵, Yuya Kimura⁶, Tadahiro Goto⁷, Hiroki Matsui⁸, Kiyohide Fushimi⁹ and Hideo Yasunaga⁵, ¹Suwa central hospital, Chino, Japan, ²Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, Hiroo, Tokyo, Japan, ³Department of Rheumatology, Dokkyo Medical University, Shimotsuga, Tochigi, Japan, ⁴Department of Real-world Evidence, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁵Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁶Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁷Department of Health Data Science, Graduate School of Data Science, Yokohama City University, Yokohama, Kanagawa, Japan, ⁸Department of Clinical Epidemiology and Health Economics, School of Public Health, Bunkyo-ku, Tokyo, Japan, ⁹Department of Health Policy and Informatics, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Neuromyelitis optica spectrum disorder (NMOSD) can coexist with systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). Due to overlapping clinical presentations and the rarity…
Abstract Number: 2432 • ACR Convergence 2025
Duffy Null Genotype and Autoantibodies Synergistically Contribute to Severe Leukopenia in Systemic Lupus Erythematosus
valerie Lewis¹, Faith Porter², Victoria Nwankwo³, John Ice⁴, Joshua Cavett⁵ and R Hal Scofield¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Langston University, Langton, OK, ³Emory University, Atlanta, GA, ⁴OKC VA Healthcare System, Oklahoma City, OK, ⁵Oklahoma Medicar Research Foundtion, Oklahoma City
Background/Purpose: Systemic lupus erythematosus (SLE) is a common, complex inflammatory autoimmune disease in which dysregulation of both innate and adaptive immune responses has been implicated…
Abstract Number: 2413 • ACR Convergence 2025
Hydroxychloroquine and Adverse Cardiovascular Outcomes in Pregnant Patients with Systemic Lupus Erythematosus
Mariana Gonzalez-Treviño¹, Ashley L Ciosek¹, Genessis Maldonado¹, Catherine Deffendall², Tania Ruiz¹, Tracy Frech¹ and Rashmi Dhital³, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³Vanderbilt University Medical Center, Brentwood, TN
Background/Purpose: Hydroxychloroquine (HCQ) is a medication used in SLE during pregnancy. An adverse effect of HCQ includes cardiotoxicity. Hormonal changes during pregnancy may trigger SLE…
Abstract Number: 2395 • ACR Convergence 2025
Analysis of histopathological changes in the placenta of patients with systemic lupus erythematosus
Bartira Melo¹, Elizabeth Avvad², Marcela lacerda², Nilson jesus², Evandro Klumb² and Guilherme Ramires de Jesus³, ¹UERJ- Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²UERJ - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Rio de Janeiro, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is more frequent in women of reproductive age and pregnancy in these patients is considered as high risk. The inflammatory…
Abstract Number: 2379 • ACR Convergence 2025
Predicting Type 1 and Type 2 SLE Activity Using the LupusPRO
Amanda Eudy¹, Megan Clowse², Meenakshi Jolly³, Dana Burshell⁴, David Pisetsky⁵, Connor Drake⁴, Tamara Somers⁶, Ralph Snyderman⁷, Kai Sun⁸, Rebecca Sadun⁸, Lisa Criscione-Schreiber⁴, Mithu Maheswaranathan⁴, Nathaniel Harris⁵, Jayanth Doss⁹ and Jennifer Rogers⁴, ¹Duke University, Raleigh, NC, ²Duke University, Chapel Hill, NC, ³Rush University, Chicago, ⁴Duke University School of Medicine, Durham, ⁵Duke University Medical Center, Durham, NC, ⁶Duke University School of Medicine, Durham, NC, ⁷Duke Center for Personalized Health Care, Durham, NC, ⁸Duke University, Durham, NC, ⁹Division of Rheumatology and Immunology, Duke University Department of Medicine, Durham, NC
Background/Purpose: The Type 1 & 2 SLE Model separates lupus disease activity into two groups: Type 1 (e.g. arthritis, rash, nephritis) and Type 2 SLE…
Abstract Number: 2202 • ACR Convergence 2025
Epidemiologic Evaluation of Postpartum Mental Health for Women Living with Systemic Lupus Erythematosus: A Population-Based Cohort Study Among Medicaid Enrollees
Alyssa Howren¹, Amadeia Rector², Sadaf Sediqi³ and Julia F Simard⁴, ¹Stanford University, Menlo Park, CA, ²Stanford University, San Francisco, CA, ³Stanford University, Palo Alto, CA, ⁴Stanford Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune rheumatic disease, predominately affecting women during their reproductive years. Despite widespread evidence that individuals with SLE…
Abstract Number: 1919 • ACR Convergence 2025
Financial insecurity and discrimination are associated with patient-reported quality of life in patients with SLE
Heather Gold¹, Yi Li¹, Peter Izmirly², Jill Buyon¹, Mala Masson³, Amit Saxena¹, H Michael Belmont⁴, Chung-E Tseng⁵ and Rebecca Anthopolos¹, ¹NYU Grossman School of Medicine, New York, NY, ²New York University Grossman School of Medicine, New York, NY, ³NYU Langone Health, New York, ⁴NYU School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, Flushing, NY
Background/Purpose: Manifestations of SLE are known to affect patient-reported outcome measures (PROs) such as physical function, fatigue, and pain. Other work has suggested economic insecurity…
Abstract Number: 1849 • ACR Convergence 2025
Time-course RNA sequencing analysis of longitudinal peripheral blood samples to elucidate the factors determining treatment resistance in systemic lupus erythematosus
Shuji Sumitomo¹, Hideki Oka², Takeshi Iwasaki³ and Koichiro Ohmura⁴, ¹Kobe City Medical Center General Hospital, Kobe city, Hyogo, Japan, ²Kobe City Medical Center General Hospital, Kobe, Japan, ³Kyoto University, Kyoto, Japan, ⁴Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) encompasses a subset of patients who exhibit resistance to standard treatments, posing a significant challenge to achieving remission. Our study…
Abstract Number: 1818 • ACR Convergence 2025
Epigenetic Profiling of Childhood-onset Lupus Reveals Distinct Epigenetic Clusters and Suggests Epigenetic Drivers of Disease Activity
Desire Casares Marfil¹, Gülşah Kavrul Kayaalp², Vafa Guliyeva², Özlem Akgün², Şeyma Türkmen³, Elif Kilic Konte⁴, Seher Şener⁵, Sezgin Sahin⁴, Ozgur Kasapcopur⁶, Betul Sozeri⁷, Selçuk Sözer Tokdemir⁸, Seza Özen⁹, Nuray Aktay Ayaz² and Amr Sawalha¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Istanbul University Faculty of Medicine, Istanbul, Turkey, ³University of Health Sciences, Umraniye Research and Training Hospital, Istanbul, Turkey, ⁴Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ⁵Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁷Health sciences university, Istanbul, Turkey, ⁸Istanbul University, Istanbul, Turkey, ⁹Hacettepe University Medical Faculty, Ankara, Turkey
Background/Purpose: Childhood-onset lupus is generally associated with a more severe disease course than adult-onset lupus. DNA methylation alterations are known to play a key role…
Abstract Number: 1718 • ACR Convergence 2025
Mortality and Hematological Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors: Impact of Pre-existing Systemic Lupus Erythematosus
Kevin Sheng-Kai Ma¹, Dominique Feterman Jimenez², You Wu³, Jenna Thomason³, Jean Liew⁴ and Namrata Singh⁵, ¹Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ²University of Washington, Seattle, ³University of Washington, Seattle, WA, ⁴Boston University, Boston, MA, ⁵University of Washington, Bellevue, WA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their safety profile in patients with pre-existing autoimmune diseases, such as systemic lupus erythematosus (SLE),…
Abstract Number: 1638 • ACR Convergence 2025
Comparison and Assessment of the All of Us Dataset for Epidemiologic Studies of Systemic Lupus Erythematosus (SLE) Among African American Women
Katherine Singleton¹, Sarah Smith², Charmayne Dunlop-Thomas³, L. Quinnette King², Lori Ann Ueberroth⁴, Edith Williams⁵, S. Sam Lim⁶, Bethany Wolf², Diane Kamen⁷ and Paula Ramos⁶, ¹Emory University School of Medicine, Atlants, GA, ²Medical University of South Carolina, Charleston, SC, ³Emory University, Atlanta, GA, ⁴Medical University of South Carolina, Charleston, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Emory University School of Medicine, Atlanta, GA, ⁷Medical University of South Carolina, Johns Island, SC
Background/Purpose: Health disparities in SLE are well established, with African American women being disproportionately impacted. Despite the known associations between sociodemographic and genetic factors with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].